Web Design for Biotech Companies: What Actually Works

A biotech company's website had one visitor who spent 47 minutes on it — going through the science pages, the pipeline, the team bios, reading every publication link.

That visitor was the head of business development at a major pharmaceutical company. Three months later, it became the company's first licensing partnership discussion.

The website didn't close the deal. But it did the thing a biotech website needs to do: gave a serious evaluator everything they needed to conclude that this company was worth a conversation.

That's the job.

The Biotech Website Audience Problem

Most websites are designed for one primary audience. A biotech website must work for three:

Investors evaluate commercial potential, team quality, competitive position, and stage of development. They're looking for evidence of a compelling opportunity and a credible team to execute it. They're not scientists — they want clear, jargon-lite communication about what the company does and why it matters.

Scientific and clinical partners evaluate the science, the mechanism, the evidence base, the team's credentials, and the quality of the intellectual property. They are scientists — they want technical depth, precision, and referenced evidence. They'll lose confidence if the science is oversimplified or contains claims that aren't supported.

Talent evaluates the company's mission, culture, leadership, funding, and scientific direction. They're often reading the website after a job posting or networking introduction to decide whether to engage further. They need a combination of scientific credibility (is this serious science?) and organisational culture signals (is this somewhere I'd want to work?).

One website, three audiences. The design challenge is structuring content so each audience can find what they need without the site feeling fragmented.

Homepage: The Positioning Statement First

The biotech homepage has one primary job: communicate clearly what the company is working on, for what patients or applications, at what stage of development, and why it matters.

This sounds obvious. Most biotech homepages fail it by:

• Leading with a vague mission statement ("improving lives through innovation")
• Omitting the indication area or being vague about it
• Not stating the development stage
• Using imagery that's generic (electron microscopes, hands in lab coats) rather than specific to the company's work
• Burying the value proposition below a visual design showcase

What works instead:

A headline that states the company's focus specifically: "Developing small molecule inhibitors targeting KRAS G12D in pancreatic cancer."

A sub-headline that adds the stage and the differentiator: "Phase 1 clinical stage. Our approach targets previously undruggable KRAS mutations using a proprietary allosteric inhibition platform."

Then a brief expansion for the non-scientist: what this means in terms of patient need, current standard of care limitations, and why this approach is different.

The website homepage design guide covers the structural principles that work across B2B websites — applied to biotech specifically, the key adaptation is leading with precision over aspiration.

Science/Platform Page: Technical Depth With Accessible Entry

The science page is where the scientific and clinical audience evaluates your company. It's the page that determines whether a serious biotech business development professional continues engaging or closes the tab.

Structure that works:

1. Plain language overview — what the platform is, what problem in biology it addresses, what type of medicines or applications it produces. 2–3 sentences for the non-specialist.

2. Mechanism of action — for drug developers: clear description of the mechanism, with diagram if possible. For diagnostics: the assay principle, the biomarker, the clinical question it answers.

3. Differentiation from existing approaches — what is it about this approach that's different from what's been tried before? This is the most important content on the page for a scientific audience.

4. Evidence — publications, presentations, key data points. Not full papers on the page — linked references and key findings stated clearly.

5. Breadth / applicability — if the platform applies to multiple indications or product types, show the range without overextending the scientific claim.

Pipeline Page: Clarity Over Completeness

The pipeline page is often the most visited page after the homepage for investor and partner audiences. It needs to communicate programme status clearly, quickly.

What works:

A table or visual pipeline graphic showing each programme with: indication, development stage (discovery, preclinical, IND-enabling, Phase 1, Phase 2, Phase 3), and expected milestones.

For each programme: a brief (2–3 sentence) description of the unmet need, the molecule or approach, and the development rationale.

Common mistakes:

Showing too many early-stage programmes as a signal of breadth — a long discovery pipeline with nothing in the clinic reads as a research organisation, not a drug development company.

Using stage terminology inconsistently — if one programme is "IND-enabling" and another is "pre-clinical," ensure these mean the same thing and are applied consistently.

Omitting expected milestones — investors and partners are evaluating catalysts. "Phase 1 initiation expected H2 2027" is a specific, useful data point. "Currently in clinical development" is not.

Team Page: Credibility Is Built Through People

In biotech, the team page carries more credibility weight than in almost any other industry. Scientific credibility is assessed through institutional affiliations, publications, and track record. Commercial credibility is assessed through previous company-building experience.

What the team page needs:

• Full professional bios — not three-sentence summaries. Scientific founders should have their publication records and institutional backgrounds documented. Commercial leaders should have deal records and previous company experience.
• Links to Google Scholar, LinkedIn, PubMed profiles — allow a visitor to do their own due diligence directly from the page.
• The scientific advisory board, prominently featured. In early-stage biotech, the SAB is often a critical credibility signal — it shows which senior researchers have reviewed the science and found it credible enough to lend their name.
• Photographs that look professional and current, not stock photography.

Visual Design Principles for Biotech

Avoid the sector clichés. Every biotech website has electron microscope imagery, double helix graphics, and cells dividing in slow-motion video. This visual language says "biotech" but doesn't say anything about your specific company. See the life sciences branding guide for visual differentiation principles that still signal scientific credibility.

Colour: Clean, precise palettes perform well. Many successful biotech websites use near-white backgrounds with strong typographic hierarchy and one distinctive accent colour. Avoid overcrowded colour palettes — precision in design signals precision in science.

Typography: Legibility is the primary requirement — investors and scientists read substantial amounts of text on biotech websites. A clean sans-serif for body text, a distinctive display typeface for headings. Don't sacrifice legibility for visual interest.

Data visualisation: Charts, mechanism diagrams, and pipeline graphics are part of the visual identity for a biotech company. Invest in well-designed data visualisation — poorly designed charts undermine scientific credibility even when the underlying data is strong.

Mobile: Increasingly important. Investors read websites on phones. Job candidates browse on mobile. Design for mobile from the start, not as an afterthought.

What to Prioritise at Each Stage

Pre-seed to Seed: A minimal, clean website that clearly states the company's focus, team, and scientific approach. Don't over-invest — focus on getting the key pages (home, science, team) right.

Series A to B: Full website with pipeline page, comprehensive team section, and publication-linked science content. Should be able to stand up to serious investor and partner due diligence.

Pre-Phase 2 / partnership stage: Investor relations section, detailed pipeline with milestones, clinical data communication if available, and partnership inquiry pathways.

Commercial preparation: Patient and healthcare professional-facing communication, potentially separate from the corporate site. Regulatory-reviewed content. Commercial product information.